BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Semaglutide (Rybelsus) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Semaglutide (Rybelsus)\, from ClinicalTri
 als.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06050577-11056@assetmemo.bio
DTSTAMP:20261121T004118Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:Semaglutide (Rybelsus): Phase 2 readout est. (NCT06050577)
DESCRIPTION:Semaglutide (Rybelsus)\, phase 2\, Type 2 Diabetes.\nStudy: The
  Effect of Oral Semaglutide on Bone Turnover in Patients With T2D: a Rando
 mized Placebo-controlled Clinical Trial\nEstimated primary completion: 15 
 January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/semaglu
 tide-rybelsus#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06050577
URL:https://assetmemo.bio/drug/semaglutide-rybelsus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07401992-11056@assetmemo.bio
DTSTAMP:20261121T004118Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Semaglutide (Rybelsus): Phase 4 readout est. (NCT07401992)
DESCRIPTION:Semaglutide (Rybelsus)\, phase 4.\nStudy: Effects of Semaglutid
 e on Clinical Outcomes and Metabolic Inflammation in Psoriasis\nEstimated 
 primary completion: 28 February 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/semaglutide-rybelsus#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07401992
URL:https://assetmemo.bio/drug/semaglutide-rybelsus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06338553-11056@assetmemo.bio
DTSTAMP:20261121T004118Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Semaglutide (Rybelsus): Phase 1 readout est. (NCT06338553)
DESCRIPTION:Semaglutide (Rybelsus)\, phase 1.\nStudy: GLP-1Ra Impact on Met
 abolic Outcomes in Stage 2 T1DM While Receiving Teplizumab\nEstimated prim
 ary completion: March 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/semaglutide-rybelsus#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06338553
URL:https://assetmemo.bio/drug/semaglutide-rybelsus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06003153-11056@assetmemo.bio
DTSTAMP:20261121T004118Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Semaglutide (Rybelsus): Phase 4 readout est. (NCT06003153)
DESCRIPTION:Semaglutide (Rybelsus)\, phase 4\, Type 2 Diabetes.\nStudy: GLU
 COSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide
  Exposure at MGH\nEstimated primary completion: 31 May 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/semaglutide-rybelsus#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06003153
URL:https://assetmemo.bio/drug/semaglutide-rybelsus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06318442-11056@assetmemo.bio
DTSTAMP:20261121T004118Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Semaglutide (Rybelsus): Phase na readout est. (NCT06318442)
DESCRIPTION:Semaglutide (Rybelsus)\, phase na.\nStudy: The GAPSID Study - H
 ow GLP-1 Analogues Prevent Steroid-Induced Diabetes\nEstimated primary com
 pletion: 1 June 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /semaglutide-rybelsus#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06318442
URL:https://assetmemo.bio/drug/semaglutide-rybelsus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06446531-11056@assetmemo.bio
DTSTAMP:20261121T004118Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Semaglutide (Rybelsus): Phase 1 readout est. (NCT06446531)
DESCRIPTION:Semaglutide (Rybelsus)\, phase 1.\nStudy: Prevention of Progres
 sion of Prediabetes\, Obesity and CV Risk\nEstimated primary completion: J
 uly 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/semaglutide
 -rybelsus#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06446531
URL:https://assetmemo.bio/drug/semaglutide-rybelsus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06613854-11056@assetmemo.bio
DTSTAMP:20261121T004118Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Semaglutide (Rybelsus): Phase 4 readout est. (NCT06613854)
DESCRIPTION:Semaglutide (Rybelsus)\, phase 4\, Type 2 Diabetes.\nStudy: Eff
 ect of Early Combination Antihyperglycemic Treatment on Metabolic Control 
 in Individuals With Type 2 Diabetes\nEstimated primary completion: Septemb
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/semaglutide-
 rybelsus#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06613854
URL:https://assetmemo.bio/drug/semaglutide-rybelsus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05702931-11056@assetmemo.bio
DTSTAMP:20261121T004118Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Semaglutide (Rybelsus): Phase 4 readout est. (NCT05702931)
DESCRIPTION:Semaglutide (Rybelsus)\, phase 4.\nStudy: Semaglutide Treatment
  for Hyperglycaemia After Renal Transplantation\nEstimated primary complet
 ion: December 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/s
 emaglutide-rybelsus#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05702931
URL:https://assetmemo.bio/drug/semaglutide-rybelsus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07200622-11056@assetmemo.bio
DTSTAMP:20261121T004118Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Semaglutide (Rybelsus): Phase 2 readout est. (NCT07200622)
DESCRIPTION:Semaglutide (Rybelsus)\, phase 2.\nStudy: Oral Semaglutide in P
 atients With Alzheimer's Disease\nEstimated primary completion: 31 Decembe
 r 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/semaglutide-r
 ybelsus#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07200622
URL:https://assetmemo.bio/drug/semaglutide-rybelsus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06792422-11056@assetmemo.bio
DTSTAMP:20261121T004118Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Semaglutide (Rybelsus): Phase 4 readout est. (NCT06792422)
DESCRIPTION:Semaglutide (Rybelsus)\, phase 4.\nStudy: A Study Investigating
  Oral Semaglutide in People with Open-Angle Glaucoma\nEstimated primary co
 mpletion: August 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/semaglutide-rybelsus#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06792422
URL:https://assetmemo.bio/drug/semaglutide-rybelsus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05441267-11056@assetmemo.bio
DTSTAMP:20261121T004118Z
DTSTART;VALUE=DATE:20280817
DTEND;VALUE=DATE:20280818
SUMMARY:Semaglutide (Rybelsus): Phase 4 readout est. (NCT05441267)
DESCRIPTION:Semaglutide (Rybelsus)\, phase 4\, Type 2 Diabetes.\nStudy: A S
 tudy of Cardiovascular Events iN Diabetes Plus\nEstimated primary completi
 on: 17 August 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/s
 emaglutide-rybelsus#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05441267
URL:https://assetmemo.bio/drug/semaglutide-rybelsus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07391267-11056@assetmemo.bio
DTSTAMP:20261121T004118Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Semaglutide (Rybelsus): Phase na readout est. (NCT07391267)
DESCRIPTION:Semaglutide (Rybelsus)\, phase na.\nStudy: Pathogenesis of Chro
 nic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty
  Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide.\nEstima
 ted primary completion: 31 December 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/semaglutide-rybelsus#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07391267
URL:https://assetmemo.bio/drug/semaglutide-rybelsus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07254572-11056@assetmemo.bio
DTSTAMP:20261121T004118Z
DTSTART;VALUE=DATE:20290801
DTEND;VALUE=DATE:20290802
SUMMARY:Semaglutide (Rybelsus): Phase 4 readout est. (NCT07254572)
DESCRIPTION:Semaglutide (Rybelsus)\, phase 4\, Atherosclerotic Cardiovascul
 ar Disease.\nStudy: Anti-atherosclerotic Efficacy of Selected Antidiabetic
  Drugs in Patients With Coronary Artery Disease and Pre-diabetes\nEstimate
 d primary completion: 1 August 2029. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/semaglutide-rybelsus#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07254572
URL:https://assetmemo.bio/drug/semaglutide-rybelsus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07221214-11056@assetmemo.bio
DTSTAMP:20261121T004118Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Semaglutide (Rybelsus): Phase 2 readout est. (NCT07221214)
DESCRIPTION:Semaglutide (Rybelsus)\, phase 2.\nStudy: GLP-1 Receptor Agonis
 ts to Decrease Ethanol and CVD Risk in HIV\nEstimated primary completion: 
 31 October 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sema
 glutide-rybelsus#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07221214
URL:https://assetmemo.bio/drug/semaglutide-rybelsus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07642635-11056@assetmemo.bio
DTSTAMP:20261121T004118Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Semaglutide (Rybelsus): Phase 1/2 readout est. (NCT07642635)
DESCRIPTION:Semaglutide (Rybelsus)\, phase 1/2.\nStudy: Glucagon-Like Pepti
 de-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duc
 henne Muscular Dystrophy\nEstimated primary completion: September 2030. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/semaglutide-rybelsus#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076426
 35
URL:https://assetmemo.bio/drug/semaglutide-rybelsus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07135245-11056@assetmemo.bio
DTSTAMP:20261121T004118Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Semaglutide (Rybelsus): Phase 2 readout est. (NCT07135245)
DESCRIPTION:Semaglutide (Rybelsus)\, phase 2.\nStudy: Improved Treatment an
 d Monitoring of Alzheimer's Disease\nEstimated primary completion: 30 Sept
 ember 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/semagluti
 de-rybelsus#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07135245
URL:https://assetmemo.bio/drug/semaglutide-rybelsus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07923630-11056@assetmemo.bio
DTSTAMP:20261121T004118Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Semaglutide (Rybelsus): Phase 2 readout est. (NCT07923630)
DESCRIPTION:Semaglutide (Rybelsus)\, phase 2.\nStudy: Validation & Interven
 tion Testing for Aging\, Longevity and Healthspan\nEstimated primary compl
 etion: December 2030. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /semaglutide-rybelsus#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07923630
URL:https://assetmemo.bio/drug/semaglutide-rybelsus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
